Liver transplantation for hepatocellular carcinoma: A proposal of a prognostic scoring system

被引:182
作者
Iwatsuki, S [1 ]
Dvorchik, I [1 ]
Marsh, JW [1 ]
Madariaga, JR [1 ]
Carr, B [1 ]
Fung, JJ [1 ]
Starzl, TE [1 ]
机构
[1] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Dept Surg, Med Ctr, Pittsburgh, PA 15213 USA
关键词
D O I
10.1016/S1072-7515(00)00688-8
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The current staging system of hepatocellular carcinoma established by the International Union Against Cancer and the American Joint Committee on Cancer does not necessarily predict the outcomes after hepatic resection or transplantation. Study Design: Various clinical and pathologic risk factors for tumor recurrence were examined on 344 consecutive patients who received hepatic transplantation in the presence of nonfibrolamellar hepatocellular carcinoma to establish a reliable risk scoring system. Results: Multivariate analysis identified three factors as independently significant poor prognosticators: 1) bilobarly distributed tumors, 2) size of the greatest tumor (2 to 5 cm and > 5 cm), and 3) vascular invasion (microscopic and macroscopic). Prognostic risk score (PRS) of each patient was calculated from the relative risks of multivariate analysis. The patients were grouped into five grades of tumor recurrence risk: grade 1: PRS=0 to <7.5; grade 2: PRS=7.5 to less than or equal to 11.0; grade 3: PRS > 11.0 to 15.0; grade 4: PRS greater than or equal to 15.0; and grade 5: positive node, metastasis, or margin. The proposed PRS system correlated extremely well with tumor-free survival after liver transplantation (100%, 61%, 40%, 5%, and 0%, from grades 1 to 5, respectively, at 5 years), but current pTNM staging did not. Conclusions: 1) Patients with grades 1 and 2 are effectively treated with liver transplantation, 2) patients with grades 4 and 5 are poor candidates for liver transplantation, and 3) patients with grade 1 do not benefit from adjuvant chemotherapy. (J Am Coll Surg 2000; 131:389-334. (C) 2000 by the American College of Surgeons).
引用
收藏
页码:389 / 394
页数:6
相关论文
共 22 条
[1]  
*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN, P101
[2]   LIVER RESECTION VERSUS TRANSPLANTATION FOR HEPATOCELLULAR-CARCINOMA IN CIRRHOTIC-PATIENTS [J].
BISMUTH, H ;
CHICHE, L ;
ADAM, R ;
CASTAING, D ;
DIAMOND, T ;
DENNISON, A .
ANNALS OF SURGERY, 1993, 218 (02) :145-151
[3]   Hepatocellular carcinoma and cirrhosis - Results of surgical treatment in a European series [J].
Fuster, J ;
GarciaValdecasas, JC ;
Grande, L ;
Tabet, J ;
Bruix, J ;
Anglada, T ;
Taura, P ;
Lacy, AM ;
Gonzalez, X ;
Vilana, R ;
Bru, C ;
Sole, M ;
Visa, J .
ANNALS OF SURGERY, 1996, 223 (03) :297-302
[4]  
*INT UN CANC, 1997, TNM CLASS MAL TUM, P66
[5]   HEPATIC RESECTION VERSUS TRANSPLANTATION FOR HEPATOCELLULAR-CARCINOMA [J].
IWATSUKI, S ;
STARZL, TE ;
SHEAHAN, DG ;
YOKOYAMA, I ;
DEMETRIS, AJ ;
TODO, S ;
TZAKIS, AG ;
VANTHIEL, DH ;
CARR, B ;
SELBY, R ;
MADARIAGA, J .
ANNALS OF SURGERY, 1991, 214 (03) :221-229
[6]   PROGNOSTIC FACTORS OF HEPATOCELLULAR-CARCINOMA IN PATIENTS UNDERGOING HEPATIC RESECTION [J].
IZUMI, R ;
SHIMIZU, K ;
II, T ;
YAGI, M ;
MATSUI, O ;
NONOMURA, A ;
MIYAZAKI, I .
GASTROENTEROLOGY, 1994, 106 (03) :720-727
[7]  
Lau H, 1998, CANCER, V83, P2303
[8]   Liver transplantation for small hepatocellular carcinoma:: The tumor-node-metastasis classification does not have prognostic power [J].
Llovet, JM ;
Bruix, J ;
Fuster, J ;
Castells, A ;
Garcia-Valdecasas, JC ;
Grande, L ;
Franca, A ;
Brú, C ;
Navasa, M ;
Ayuso, MD ;
Solé, M ;
Real, MI ;
Vilana, R ;
Rimola, A ;
Visa, J ;
Rodés, J .
HEPATOLOGY, 1998, 27 (06) :1572-1577
[9]   The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: A pilot study [J].
Marsh, JW ;
Dvorchik, I ;
Subotin, M ;
Balan, V ;
Rakela, J ;
Popechitelev, EP ;
Subbotin, V ;
Casavilla, A ;
Carr, BI ;
Fung, JJ ;
Iwatsuki, S .
HEPATOLOGY, 1997, 26 (02) :444-450
[10]  
Marsh JW, 2000, CANCER, V88, P538, DOI 10.1002/(SICI)1097-0142(20000201)88:3<538::AID-CNCR7>3.0.CO